| Name | Title | Contact Details |
|---|---|---|
Paulette Gangemi |
Senior Director, Employee Relations and Employment Practices (HR) | Profile |
Ansun BioPharma is a clinical stage biopharmaceutical company focused on the development of unique host-directed anti-viral therapies for respiratory viruses. Ansun BioPharma has two products in late stage clinical development. Fludase is a first-in-class broad-spectrum investigational therapeutic agent to treat all forms of influenza, including pandemic variants and drug-resistant variants that cannot be treated by any currently approved flu therapies, including H1N1, H5N1 and H7N9. Paradase is an investigational nebulized drug which is designed to target the receptor for parainfluenza viruses and is being evaluated in a Phase 2 trial for the treatment of lower tract parainfluenza infection in immunocompromised patients.
BIND Biosciences, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cydan Development is an orphan drug accelerator that identifies and de-risks programs with therapeutic and commercial potential.
Hinsdale Hematology-Oncology Associates is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accera div Nestle Corp is a Broomfield, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.